TAS2R8 and neoplasm: Moreover, in vivo experiments with mice showed that the subcutaneous injection of SK-N-BE(2)C cells, overexpressing TAS2R8 or TAS2R10 by stable transfection, reduced tumour incidence by 80% and 30%, respectively.